Development of a Rapid Diagnostic Test for Multidrug-Resistant Tuberculosis Using CRISPR-Based Technology

Project Abstract

The emergence of multidrug-resistant tuberculosis (MDR-TB) poses a significant challenge to global health, necessitating the development of rapid, accurate, and cost-effective diagnostic methods to enhance disease management and control. This research focuses on leveraging CRISPR-based technology to create an innovative diagnostic tool capable of detecting MDR-TB swiftly and accurately at the point of care. Traditional diagnostic methods such as sputum smear microscopy, culture, and molecular techniques like Xpert MTB/RIF, while useful, often face limitations related to sensitivity, time consumption, and infrastructural requirements, which restrict their effectiveness in resource-limited settings. By harnessing the specificity of CRISPR-Cas systems, particularly Cas12 and Cas13 nucleases, this study aims to develop a point-of-care diagnostic assay that can identify Mycobacterium tuberculosis DNA and its resistance-conferring mutations directly from clinical samples within an hour. The research involved designing guide RNAs tailored to common resistance mutations in genes such as rpoB, katG, and inhA, which are associated with resistance to rifampicin and isoniazid, the primary drugs used in TB therapy. A multiplexed assay was optimized to enhance detection capabilities, utilizing fluorescent or lateral flow readout options suitable for field deployment. Validation of the assay was conducted using clinical samples obtained from TB-endemic regions, benchmarked against gold-standard methods to evaluate sensitivity, specificity, turnaround time, and cost-effectiveness. The results demonstrated that the CRISPR-based diagnostic platform achieved a sensitivity of over 95% in detecting MDR mutations, with a turnaround time significantly shorter than conventional methods. Additionally, the assay exhibited high specificity, with minimal false positives, and demonstrated robust performance in diverse sample types under varying environmental conditions. The study discusses the potential impact of deploying this technology in low-resource settings, emphasizing its simplicity, rapidity, and affordability. Challenges such as reagent stability, the need for minimal training, and scalability were addressed to facilitate widespread implementation. The findings underscore the feasibility of integrating CRISPR-based diagnostics into existing health systems, offering a transformative approach to combating MDR-TB by enabling early detection, timely treatment initiation, and improved patient outcomes. This research contributes to the growing field of CRISPR diagnostics and provides a blueprint for future innovations targeting other infectious diseases. Overall, the developed platform represents a significant advancement towards real-time, accessible TB resistance testing, aligning with global efforts to eradicate TB and curb antimicrobial resistance.

Project Overview

What This Project Is About

This project focuses on developing a new test to quickly identify if a person has tuberculosis (TB) that is resistant to common drugs. It uses a modern technology called CRISPR, which can find specific DNA sequences in bacteria. The goal is to create a simple, fast, and accurate way to detect drug-resistant TB, helping health workers diagnose and treat the disease more effectively.

The Problem It Addresses

Multidrug-resistant TB (MDR-TB) is a form of tuberculosis that does not respond to the usual medicines, making it harder and more expensive to treat. Current testing methods can take weeks to give results and often require expensive laboratory facilities. This delay can lead to ongoing transmission and worsened health outcomes. Developing a rapid, reliable test will help catch resistant cases early and improve patient care.

Objectives of the Project

1. Design a CRISPR-based testing method for specific genetic markers of drug resistance in TB bacteria.
2. Develop a simple protocol that can be used outside specialized labs, suitable for resource-limited settings.
3. Test the accuracy and speed of the new diagnostic method on clinical samples.
4. Compare the new test's performance with existing laboratory methods to assess its effectiveness.

What You Will Do Step by Step

1. Research existing TB resistance genes and identify targets for detection.
2. Design CRISPR tools that can recognize these specific DNA sequences.
3. Create a testing protocol using these CRISPR tools on laboratory samples containing TB bacteria.
4. Collect clinical samples from patients suspected of having TB.
5. Apply the new test on these samples and record how long it takes and whether it can correctly identify resistant cases.
6. Analyze and compare the test results with traditional methods for accuracy and speed.
7. Identify any challenges or limitations and suggest improvements.

Expected Outcome

The project aims to produce a rapid, accurate, and affordable test for detecting multidrug-resistant TB. Such a test could help health organizations diagnose resistant cases faster, leading to better patient treatment and controlling the spread of resistant TB strains. Ultimately, this approach has the potential to improve public health outcomes, especially in areas with limited laboratory facilities.